26 results
6-K
EX-1.1
ENLV
Enlivex Therapeutics Ltd
29 May 24
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
4:20pm
not have a Material Adverse Effect. There is no pending, completed or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration
424B5
ENLV
Enlivex Therapeutics Ltd
29 May 24
Prospectus supplement for primary offering
4:15pm
that was rendered in the same matter between the same parties and that is still valid; or
at the time the action was brought in the foreign court, a lawsuit
6-K
EX-10.1
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Report of Foreign Private Issuer
4:02pm
or, to the Company’s knowledge, threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge
424B5
ENLV
Enlivex Therapeutics Ltd
30 Dec 22
Prospectus supplement for primary offering
4:01pm
and that is still valid; or
at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending
F-3
ENLV
Enlivex Therapeutics Ltd
29 Apr 22
Shelf registration (foreign)
8:14am
in the same matter between the same parties and that is still valid; or
at the time the action was brought in the foreign court, a lawsuit in the same matter
6-K
EX-99.1
m2joly
19 Nov 21
Condensed Consolidated Financial Statements
4:30pm
6-K
EX-99.1
lau2j8h jo
6 Aug 21
Condensed Consolidated Financial Statements
4:31pm
6-K
EX-1.1
ezi7llz42kpp9jh
12 Feb 21
Enlivex Announces Closing of Previously Announced Bought Deal Offering of Approximately $46.0 Million Ordinary Shares
5:17pm
424B5
vuw id8my6
10 Feb 21
Prospectus supplement for primary offering
5:22pm
424B5
921jzqatdj
9 Feb 21
Prospectus supplement for primary offering
4:56pm
6-K
EX-10.1
sbe7m8xv34kuusw
22 Oct 20
Report of Foreign Private Issuer
8:47am
424B5
3p3q2w
22 Oct 20
Prospectus supplement for primary offering
8:45am
6-K
EX-1.1
52y rurvhuv6y1r
5 Mar 20
Report of Foreign Private Issuer
8:16am
424B5
mb1xsg7irswlg12ck w1
3 Mar 20
Prospectus supplement for primary offering
5:13pm
6-K
EX-1.1
xdsxzban c9b6f1k9v
26 Feb 20
Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering
4:15pm
424B5
jghv2xcdsj m0xqrin
26 Feb 20
Prospectus supplement for primary offering
8:23am
424B5
sbh agw282y
20 Nov 19
Prospectus supplement for primary offering
4:46pm
424B3
le98j9z
10 Jul 19
Prospectus supplement
8:18am
F-3
zfb1kqe
28 Jun 19
Shelf registration (foreign)
9:48am
F-3
kqdgzmwjklqh3p
7 Jun 19
Shelf registration (foreign)
3:31pm